Trial Profile

Pilot Study of the Efficacy and Safety of Cluster of Differentiation Antigen 19 (CD19) /Cluster of Differentiation Antigen 22 (CD22) CART in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD22 chimeric antigen receptor T cell therapy-Shanghai Unicar-Therapy Bio-medicine Technology (Primary) ; Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary) ; Cyclophosphamide; Decitabine; Fludarabine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Sponsors Shanghai Unicar-Therapy Bio-medicine Technology

27 Nov 2023 Planned End Date changed from 1 Jan 2024 to 31 Dec 2025.
27 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 31 Dec 2024.
18 May 2022 Planned End Date changed from 1 Jan 2021 to 1 Jan 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com